ReviewJournal of immunology (Baltimore, Md. : 1950)2015
Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases.
Review in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review.Pharmaceutics · 2026Review
- Application of the miRNAs as biomarkers and therapeutic strategies in periodontal inflammation.Frontiers in pharmacology · 2026Review
- Review
- Review
- Hybridizing clinical translatability with enzyme-free DNA signal amplifiers: recent advances in nucleic acid detection and imaging.Biomaterials science · 2021Review
- The clinical potential of circulating microRNAs in obesity.Nature reviews. Endocrinology · 2019Review
- Epigenetics in osteoarthritis: Novel spotlight.Journal of cellular physiology · 2019Review
- Beyond sequence homology: Cellular biology limits the potential of XIST to act as a miRNA sponge.PloS one · 2019Article
- Editorial focus: understanding off-target effects as the key to successful RNAi therapy.Cellular & molecular biology letters · 2019Review
- miR-221-3p Drives the Shift of M2-Macrophages to a Pro-Inflammatory Function by Suppressing JAK3/STAT3 Activation.Frontiers in immunology · 2019Article
- Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease.World journal of gastroenterology · 2018Review
- MicroRNAs and immunity in periodontal health and disease.International journal of oral science · 2018Review
- Expression profile of microRNAs following bone marrow-derived mesenchymal stem cell treatment in lipopolysaccharide-induced acute lung injury.Experimental and therapeutic medicine · 2018Article
- Editorial focus: entering into the non-coding RNA era.Cellular & molecular biology letters · 2018Review
- Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease.Frontiers in immunology · 2018Review
- MicroRNA Signature of Cigarette Smoking and Evidence for a Putative Causal Role of MicroRNAs in Smoking-Related Inflammation and Target Organ Damage.Circulation. Cardiovascular genetics · 2017Article
- Shifting from Correlation to Causation: Challenges for the Future of Unbiased Molecular Studies in Inflammatory Lung Disease.American journal of respiratory and critical care medicine · 2017Article
- miRNAsong: a web-based tool for generation and testing of miRNA sponge constructs in silico.Scientific reports · 2016Article
- Mitochondrial Epigenetics and Environmental Exposure.Current environmental health reports · 2016Review
- Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
MicroRNAs (miRNAs) are endogenous oligoribonucleotides with exciting therapeutic potential. Early studies established a clear role for miRNAs in leukocyte biology. The first miRNA-based therapy, miravirsen, is now in phase 2 clinical trials, making the reality of these therapies undeniable. The capacity for miRNAs to fine-tune inflammatory signaling make them attractive treatment targets for immunological diseases. Nonetheless, the degree of redundancy among miRNAs, coupled with the promiscuity of miRNA binding sites in the transcriptome, require consideration when designing miRNA-directed interventions. Altered miRNA expression occurs across a range of inflammatory conditions, including inflammatory bowel disease, arthritis, and diabetes. However, very few studies successfully treated murine models of immunological diseases with miRNA-based approaches. While discussing recent studies targeting miRNAs to treat immunological conditions, we also reflect on the risks of miRNA targeting and showcase some newer delivery systems that may improve the pharmacological profile of this class of therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.